STAGE IV LIP AND ORAL CAVITY CANCER AJCC V8
Clinical trials for STAGE IV LIP AND ORAL CAVITY CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV LIP AND ORAL CAVITY CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV LIP AND ORAL CAVITY CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine combo aims to train immune system against advanced head and neck cancer
Disease control Recruiting nowThis early-phase trial tests a vaccine made from a patient's own tumor cells, alone or with the immunotherapy drug pembrolizumab, for head and neck cancer that has come back or spread. The goal is to find the safest dose and see if the vaccine helps the immune system fight the ca…
Matched conditions: STAGE IV LIP AND ORAL CAVITY CANCER AJCC V8
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New combo therapy aims to shrink tumors in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests two drugs, cabozantinib and nivolumab, in people with advanced melanoma or head and neck cancer that has spread. The goal is to see if the combination can shrink or stabilize tumors, and whether certain biomarkers in the tumor can predict who responds best. About…
Matched conditions: STAGE IV LIP AND ORAL CAVITY CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
Cholesterol drug boosts immunotherapy in head and neck cancer trial
Disease control Recruiting nowThis study tests whether adding lovastatin (a common cholesterol drug) to pembrolizumab (an immunotherapy) can shrink tumors in people with head and neck cancer that has returned or spread. About 28 adults whose cancer has a specific marker (PD-L1 CPS ≥ 1) will receive both drugs…
Matched conditions: STAGE IV LIP AND ORAL CAVITY CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 08, 2026 13:17 UTC
-
New combo therapy aims to outsmart resistant head and neck cancer
Disease control Recruiting nowThis study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…
Matched conditions: STAGE IV LIP AND ORAL CAVITY CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 08, 2026 13:10 UTC
-
Remote hearing tests could save cancer Patients' hearing
Knowledge-focused Recruiting nowThis study looks at whether offering hearing tests near home or online can help more head and neck cancer patients get their hearing checked during treatment. Chemotherapy and radiation can cause hearing loss, but regular monitoring can catch it early. The study will enroll 118 a…
Matched conditions: STAGE IV LIP AND ORAL CAVITY CANCER AJCC V8
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:05 UTC